Tag: PNH

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria

Jason Shafrin

That is the tile of my recent paper in the Journal of Medical Economics with co-authors Kyi-Sin Than, Sanjana Muthukrishnan, Jincy Paulose, Ver Bilano and Nicholas Kuypers. The abstract is below: ObjectiveParoxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a…

A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria

Jason Shafrin

That is the title of my recent paper with co-authors Denise Clayton, Glorian Yen, Lincy Geevarghese, Yulin Shi Anem Waheed. The abstract is below. IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease associated with complications that increase morbidity, such as thrombosis and chronic kidney disease. Limited data exist regarding complications among treated patients outside…

Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis

Jason Shafrin

That is the title of my new paper published today in Clinical and Applied Thrombosis/Hemostasis with co-authors Denise Clayton, Glorian Yen, Soyon Lee, Lincy Geevarghese, Yulin Shi, Luyang He, Ying Shen, and Anem Waheed. The abstract is below: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder commonly treated with complement inhibitors such as…